Clinical trials: Refractory Metastatic Colorectal Cancer
Refractory Metastatic Colorectal Cancer
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer
- Trial name
- NCT02860546
- Testing
- TAS-102, nivolumab
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Colorectal Cancer, Metastatic Cancer
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Trial name
- NCT00089401
- Testing
- isolated perfusion, melphalan, conventional surgery
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
This phase II trial studies how well CBX-12 works in treating patients with microsatellite stable colorectal cancer that has spread to other parts of the body (metastatic) and is no longer responding to chemotherapy treatment…
- Conditions
- Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT06730100
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 15 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
This study is designed to evaluate the mechanism(s) of resistance to the anti-epidermal growth factor receptor (EGFR) antibody panitumumab given in combination with irinotecan in metastatic colorectal carcinoma (mCRC) patients…
- Trial name
- NCT00891930
- Testing
- Panitumumab, Ganitumab, Irinotecan
- Volunteers
- 74 people
- Sponsor
- NantBioScience, Inc.
Metastatic Cancer
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant.
- Trial name
- NCT00861107
- Testing
- AlloStim-7, percutaneous tumor cryoablation, AlloStim8 or AlloStim-9
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mirror Biologics, Inc.
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Colorectal Cancer
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.
- Trial name
- NCT03542877
- Testing
- Oral Tablet: Cabozantinib
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Fruquintinib, S-1
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
Based on the FRECO-2 study, Fruquintinib has become one of the standard third-line treatments for advanced colorectal cancer; however, its objective response rate (ORR) remains low.
- Conditions
- Fruquintinib, S-1, Raltitrexed
- Trial name
- NCT06427005
- Testing
- Fruquintinib, S-1, raltitrexed
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Meng Qiu
Colon Adenocarcinoma, High-Frequency Microsatellite Instability
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
This phase Ib/II trial studies how well anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) works in treating patients with colorectal cancer (or with other solid tumors with microsatellite instability) that has spread to other…
- Conditions
- Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Neoplasm, Rectal Adenocarcinoma
- Trial name
- NCT03436563
- Testing
- Anti-PD-L1/TGFbetaRII Fusion Protein M7824
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer
This study aims to evaluate the safety and efficacy of Immuncell-LC, the adoptive immuntherapeutic agent composed of a CIK cell agent, to treat patients with metastatic colorectal cancer, which are refractory to the 3rd-line…
- Trial name
- NCT03220984
- Testing
- Immuncell-LC intravenous infusion using a CIK cell agent
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Gangnam Severance Hospital
Metastatic Colorectal Cancer
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).
- Trial name
- NCT05093907
- Testing
- BEY1107, Capecitabine
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- BeyondBio Inc.
Colorectal Carcinoma
Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
The purpose of this study is to evaluate and quantify the dynamic modifications of tumor blood perfusion on axitinib therapy in patients with refractory mCRC for each dose of Axitinib.
- Trial name
- AXUS (NCT01486251)
- Testing
- axitinib
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable
- Trial name
- NCT05572684
- Testing
- NC410, pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 97 people
- Sponsor
- NextCure, Inc.
CRC (Colorectal Cancer)
Study of Ruxolitinib in Colorectal Cancer Patients
The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.
- Trial name
- NCT02119676
- Testing
- Ruxolitinib, Regorafenib
- Where
- 86 sites in United States, Australia and 6 more
- Volunteers
- 396 people
- Sponsor
- Incyte Corporation
Refractory Metastatic Colorectal Cancer, pMMR
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair…
- Conditions
- Refractory Metastatic Colorectal Cancer, pMMR, MSS
- Trial name
- NCT05733611
- Testing
- RP2, RP3, atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Replimune, Inc.
Metastatic Colorectal Cancer, Metastatic Colon Cancer
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in participants with…
- Trial name
- FRESCO-2 (NCT04322539)
- Testing
- Fruquintinib
- Where
- 153 sites in United States, Australia and 12 more
- Volunteers
- 691 people
- Sponsor
- Hutchison Medipharma Limited
Metastatic Cancer, Cancer, Breast
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Sarcopenia is defined as reduction in muscle mass and function according to the criteria of the European Working Group on Sarcopenia in older people.
- Conditions
- Metastatic Cancer, Cancer, Breast, Cancer Colon, Cancer, Rectum
- Trial name
- SPACE2 (NCT05154474)
- Testing
- Standard
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Weprom
Colorectal Cancer, Ovarian Cancer
A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer
This exploratory, open label study will assess the the dose-effect relationship, efficacy and safety of RO5323441 in patients with metastatic treatment-refractory colorectal or ovarian cancer.
- Trial name
- NCT01148758
- Testing
- RO5323441
- Where
- 3 sites in Belgium, Spain and 1 more
- Volunteers
- 7 people
- Sponsor
- Hoffmann-La Roche
Refractory Metastatic Colorectal Cancer
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants.
- Trial name
- NCT07361003
- Testing
- Suvemcitug injection, trifluridine/tipiracil tablets
- Where
- 6 sites in China
- Volunteers
- 464 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.